Introduction
Schizophrenia is a debilitating illness with an estimated lifetime prevalence of around 0.7% (McGrath et al., 2008) . In 2001, the World Health Organization described schizophrenia as one of the ten most disabling diseases in the world (Saraceno et al., 2005) . It affects nearly all areas of patients' social, family and professional lives. Its cost for society is high, both directly (hospitalizations, treatment, dysfunctional social skills) and indirectly (loss of productivity) (McGrath et al., 2008) . Its course can be marked by resistance to antipsychotic treatment, meaning that therapeutic support is sometimes challenging for the practitioner, with results that are partial and unsatisfactory.
Despite the development of a new generation of molecules, bringing greater efficacy and fewer side effects, some patients still fail to respond to treatment. The rate of treatmentresistant schizophrenia (TRS) is estimated to be between 30 and 60%, depending on which criteria are used (Solanki et implying that pharmacodynamic factors come into play in treatment resistance, or nonlinear pharmacokinetics, which would justify an increasing dose strategy in order to achieve an effective olanzapine blood concentration. The first option would appear to be the most relevant.
In the present study, we assessed the pharmacokinetics of olanzapine at both conventional and high doses. We hypothesized that there is a linear dose-concentration relationship at very high doses, just as the literature have highlighted it at doses < 60 mg/d.
Methods

Patient population
Participants were recruited at Rennes University Psychiatric Hospital either as inpatients or as outpatients. We included patients who had been diagnosed with schizophrenia or schizoaffective disorder in accordance with DSM-IV criteria and were being treated with olanzapine. Exclusion criteria were other DSM-IV diagnoses (bipolar disorder, autism, etc.) and addictions (alcohol, cannabis, heroin, cocaine, etc.).
The participants were aware of the purpose of the study, and gave their informed consent. The study was approved by the Human Research Ethics Committee of Rennes University Hospital (Brittany, France) and was conducted in accordance with the Declaration of Helsinki and its subsequent revisions.
Study design
We implemented a prospective, observational, open-study design. In accordance with the literature, patients were included after a steady-state olanzapine regimen lasting at least 8 days (Callaghan et al., 1999) . They were assessed once, either in the course of their hospitalization or during an outpatient consultation.
Clinical assessment
The clinical assessment was conducted by an experienced psychiatrist.
We recorded the participants' general characteristics, including age and sex, tobacco, tea and/or coffee consumption, psychiatric, medical and surgical history, olanzapine treatment history, and history of other treatments.
In line with the literature, therapeutic side effects were assessed with two scales: the Extrapyramidal Syndrome Rating Scale (ESRS), which focuses on neurological side effects, and the Udvalg for Kliniske Undersogelser (UKU), a more general scale that measures psychic, neurological, neurovegetative and other side effects. Schizophrenic symptoms were assessed by means of the Positive and Negative Syndrome Scale (PANSS). The Clinical Global Impression scale (CGI) yielded a qualitative assessment.
Biological assessment 2.2.2.1. Methodology
In order to study trough concentrations of olanzapine and N-desmethyl olanzapine blood levels, blood samples were taken at least 21-24 hours after the last dose. For patients who were on high doses taken twice daily (4 patients), blood sampling was done 12 hours after the last dose.
Patients on very high-dose olanzapine (> 60 mg/d) underwent weekly biological assessments (blood count, liver function) and electrocardiograms.
Serum sampling
The serum samples were collected as follows: 7-10 ml of venous blood was collected in vacuum tubes containing heparin directly in the ward during routine blood tests.
The analyses were performed on a Thermo™ (San Jose, CA, USA) TSQ Quantum HPLC- 
Statistical analyses
Statistical analyses were performed on all included and assessed patients (intention-to-treat analysis) with R software (http://www.R-project.org/). All results are reported as means ± SD for continuous variables and rate for discrete variables. In line with the literature, the UKU subscale scores are described in terms of side effect occurrences. ESRS subcale scores are reported as means ± SD. The significance threshold for all the tests was set at 5% (p < 0.05).
A descriptive analysis of clinical characteristics and the dose-concentration relationship was carried out for the whole group. For the dose-concentration relationship, after calculating
Pearson's correlation coefficient, we used a linear model to assess the effects of sex, age, body mass index (BMI) tobacco (number of cigarettes per day), and coffee/tea consumption.
Results
A total of 50 patients were included in the study.
Whole group analysis
Clinical characteristics are summarized in Table 1 . Age in the total sample ranged between 19 and 60 years. Illness severity, as assessed by the mean score on the severity scale of the CGI, was moderate.
Co-medications were benzodiazepine (12 patients; 26.09%), anticonvulsants (3; 6.52%), other neuroleptics (cyamemazine or loxapine) (11; 23.91%), antiparkinsonism drugs (3; 6.52%), and antidepressants (5; 10.87%). Pharmacological and biological characteristics are summarized in Table 2. 3.1.1. Dose-concentration relationship In two of them, loxapine or cyamemazine had been co-prescribed. Three patients who were treated with 20 (OTC = 34.1 ng/ml), 30 (OTC = 60 ng/ml) or 40 mg/d (OTC = 71.8 ng/ml) had akathisia. All three of them were also receiving loxapine or cyamemazine. All the neurological side effects were given light or moderate intensity ratings.
Discussion
Ours was the first study to explore the pharmacokinetics of olanzapine used at doses above 60 mg/d in patients with schizophrenia.
Clinical considerations
Our sample comprised a majority of men (60%) and smokers (70%), which is in accordance 
Concentration-tolerance relationship
In our sample, olanzapine treatment was well tolerated, particularly with regard to neurological features. This result is in accordance with the literature (Callaghan et al., 1999; Mauri et al., 2007) . The neurological side effects we observed were in patients treated with doses between 10 and 80 mg/d, but the fact that they had co-prescriptions for other antipsychotics raises the issue of how far olanzapine was actually responsible for these effects. However, it must be pointed out that the observational design of our study leave us with a positively selected sample. In fact, patients who do not tolerate olanzapine on any dose may have been discontinued from treatment early on. Therefore, the interpretation of these results must be restricted to a descriptive analysis of our sample and can not be generalized. to increase appetite and disturb metabolism. Our study was not designed to assess these aspects (single assessment).
Conclusion
To conclude, our study yielded one main result: the linearity of the dose concentration 4.14 ± 0.22 Improvement scale (n = 37) 25 (68%) Figure   Fig. 1 . Relationship between trough olanzapine concentration and daily oral dose of olanzapine.
